Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

• Revenue in USD (TTM)2.20m
• Net income in USD-37.88m
• Incorporated1987
• Employees15.00

• Location
  Seelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
• Phone+1 (646) 293-2100
• Fax+1 (858) 436-8155
• Websitehttps://seelostherapeutics.com/